The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K

ABSTRACT Antimicrobial peptides (AMPs) have great potential to be developed as topical treatments for microbial infections of the skin, including those caused by the gram-positive human pathogen Staphylococcus aureus. Among the AMPs, temporin B (TB) is of particular interest. This 13-amino-acid-long...

Full description

Saved in:
Bibliographic Details
Main Authors: Cristina Schöpf, Magdalena Knapp, Jakob Scheler, Débora C. Coraça-Huber, Alessandra Romanelli, Peter Ladurner, Anna C. Seybold, Ulrike Binder, Reinhard Würzner, Florentine Marx
Format: Article
Language:English
Published: American Society for Microbiology 2025-06-01
Series:mSphere
Subjects:
Online Access:https://journals.asm.org/doi/10.1128/msphere.01016-24
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849423847944617984
author Cristina Schöpf
Magdalena Knapp
Jakob Scheler
Débora C. Coraça-Huber
Alessandra Romanelli
Peter Ladurner
Anna C. Seybold
Ulrike Binder
Reinhard Würzner
Florentine Marx
author_facet Cristina Schöpf
Magdalena Knapp
Jakob Scheler
Débora C. Coraça-Huber
Alessandra Romanelli
Peter Ladurner
Anna C. Seybold
Ulrike Binder
Reinhard Würzner
Florentine Marx
author_sort Cristina Schöpf
collection DOAJ
description ABSTRACT Antimicrobial peptides (AMPs) have great potential to be developed as topical treatments for microbial infections of the skin, including those caused by the gram-positive human pathogen Staphylococcus aureus. Among the AMPs, temporin B (TB) is of particular interest. This 13-amino-acid-long cationic peptide is secreted by the granular glands of the European frog Rana temporaria and represents a primary line of defense against invading pathogens. The objective of this study was to investigate the antibacterial efficacy and the mode of action of the synthetic TB analog, TB_KKG6K, in a drug-resistant clinical isolate of S. aureus and assess the peptide’s tolerance and curative potential in an in vitro infection model using three-dimensional human epidermis equivalents (HEEs). The results revealed a high bactericidal efficacy of TB_KKG6K at low micromolar concentrations. The peptide perturbed the bacterial cell membrane integrity by permeabilization and depolarization. TB_KKG6K showed no toxicity in the invertebrate mini-host model Galleria mellonella and a high level of tolerance when topically applied in HEEs. Importantly, the therapeutic potential of TB_KKG6K was confirmed in HEEs infected with S. aureus. The topical application of TB_KKG6K significantly reduced the bacterial load and lowered the pro-inflammatory response in the infected HEEs. These findings reinforce the antibacterial potential and therapeutic efficacy of TB_KKG6K against S. aureus infection, particularly in the context of a cutaneous infection.IMPORTANCEThe emergence of multidrug-resistant bacteria has rendered the exploration of novel therapeutic treatment strategies a pivotal area of research. Among the most promising candidates are amphibian-derived antimicrobial peptides (AMPs), which are ideal for the development of novel drugs due to their multifaceted mode of action. Extensive studies have been conducted on these peptides over the last decade, resulting in the development of temporin B (TB) peptide analogs that have undergone modifications to their primary sequence. These modified analogs have demonstrated enhanced antibacterial and antifungal efficacy, while exhibiting reduced hemolytic activity. TB_KKG6K has the potential to be a promising candidate for topical treatments due to its small size and high antimicrobial activity against pathogens of the human skin. In particular, it demonstrated efficacy against Staphylococcus aureus, a skin commensal that can become an opportunistic pathogen, causing a range of infections from minor skin infections to life-threatening diseases such as bacteremia and sepsis.
format Article
id doaj-art-e95afb34536b42f78aaa57e6e6aaedcd
institution Kabale University
issn 2379-5042
language English
publishDate 2025-06-01
publisher American Society for Microbiology
record_format Article
series mSphere
spelling doaj-art-e95afb34536b42f78aaa57e6e6aaedcd2025-08-20T03:30:25ZengAmerican Society for MicrobiologymSphere2379-50422025-06-0110610.1128/msphere.01016-24The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6KCristina Schöpf0Magdalena Knapp1Jakob Scheler2Débora C. Coraça-Huber3Alessandra Romanelli4Peter Ladurner5Anna C. Seybold6Ulrike Binder7Reinhard Würzner8Florentine Marx9Biocenter, Institute of Molecular Biology, Medical University of Innsbruck, Innsbruck, AustriaDepartment of Zoology, University of Innsbruck, Innsbruck, AustriaInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, AustriaResearch Laboratory for Implant Associated Infections (BIOFILM LAB), Experimental Orthopaedics, University Hospital for Orthopaedics and Traumatology, Medical University of Innsbruck, Innsbruck, AustriaDepartment of Pharmaceutical Sciences, University of Milan, Milan, ItalyDepartment of Zoology, University of Innsbruck, Innsbruck, AustriaDepartment of Zoology, University of Innsbruck, Innsbruck, AustriaInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, AustriaInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, AustriaBiocenter, Institute of Molecular Biology, Medical University of Innsbruck, Innsbruck, AustriaABSTRACT Antimicrobial peptides (AMPs) have great potential to be developed as topical treatments for microbial infections of the skin, including those caused by the gram-positive human pathogen Staphylococcus aureus. Among the AMPs, temporin B (TB) is of particular interest. This 13-amino-acid-long cationic peptide is secreted by the granular glands of the European frog Rana temporaria and represents a primary line of defense against invading pathogens. The objective of this study was to investigate the antibacterial efficacy and the mode of action of the synthetic TB analog, TB_KKG6K, in a drug-resistant clinical isolate of S. aureus and assess the peptide’s tolerance and curative potential in an in vitro infection model using three-dimensional human epidermis equivalents (HEEs). The results revealed a high bactericidal efficacy of TB_KKG6K at low micromolar concentrations. The peptide perturbed the bacterial cell membrane integrity by permeabilization and depolarization. TB_KKG6K showed no toxicity in the invertebrate mini-host model Galleria mellonella and a high level of tolerance when topically applied in HEEs. Importantly, the therapeutic potential of TB_KKG6K was confirmed in HEEs infected with S. aureus. The topical application of TB_KKG6K significantly reduced the bacterial load and lowered the pro-inflammatory response in the infected HEEs. These findings reinforce the antibacterial potential and therapeutic efficacy of TB_KKG6K against S. aureus infection, particularly in the context of a cutaneous infection.IMPORTANCEThe emergence of multidrug-resistant bacteria has rendered the exploration of novel therapeutic treatment strategies a pivotal area of research. Among the most promising candidates are amphibian-derived antimicrobial peptides (AMPs), which are ideal for the development of novel drugs due to their multifaceted mode of action. Extensive studies have been conducted on these peptides over the last decade, resulting in the development of temporin B (TB) peptide analogs that have undergone modifications to their primary sequence. These modified analogs have demonstrated enhanced antibacterial and antifungal efficacy, while exhibiting reduced hemolytic activity. TB_KKG6K has the potential to be a promising candidate for topical treatments due to its small size and high antimicrobial activity against pathogens of the human skin. In particular, it demonstrated efficacy against Staphylococcus aureus, a skin commensal that can become an opportunistic pathogen, causing a range of infections from minor skin infections to life-threatening diseases such as bacteremia and sepsis.https://journals.asm.org/doi/10.1128/msphere.01016-24antimicrobial peptidetemporin B analogStaphylococcus aureusantibacterial activitymembrane activityhuman epidermis equivalent
spellingShingle Cristina Schöpf
Magdalena Knapp
Jakob Scheler
Débora C. Coraça-Huber
Alessandra Romanelli
Peter Ladurner
Anna C. Seybold
Ulrike Binder
Reinhard Würzner
Florentine Marx
The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
mSphere
antimicrobial peptide
temporin B analog
Staphylococcus aureus
antibacterial activity
membrane activity
human epidermis equivalent
title The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
title_full The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
title_fullStr The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
title_full_unstemmed The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
title_short The antibacterial activity and therapeutic potential of the amphibian-derived peptide TB_KKG6K
title_sort antibacterial activity and therapeutic potential of the amphibian derived peptide tb kkg6k
topic antimicrobial peptide
temporin B analog
Staphylococcus aureus
antibacterial activity
membrane activity
human epidermis equivalent
url https://journals.asm.org/doi/10.1128/msphere.01016-24
work_keys_str_mv AT cristinaschopf theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT magdalenaknapp theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT jakobscheler theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT deboraccoracahuber theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT alessandraromanelli theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT peterladurner theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT annacseybold theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT ulrikebinder theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT reinhardwurzner theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT florentinemarx theantibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT cristinaschopf antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT magdalenaknapp antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT jakobscheler antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT deboraccoracahuber antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT alessandraromanelli antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT peterladurner antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT annacseybold antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT ulrikebinder antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT reinhardwurzner antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k
AT florentinemarx antibacterialactivityandtherapeuticpotentialoftheamphibianderivedpeptidetbkkg6k